Literature DB >> 18090695

Anesthesia outcomes in a randomized double-blind trial of sevoflurane and thiopental for induction of general anesthesia in electroconvulsive therapy.

Keith G Rasmussen1, Daniel R Laurila, Bret M Brady, Christy L Lewis, Kimberly D Niemeyer, Norazlina M Sun, Marie E S Marienau, W Michael Hooten, Darrell R Schroeder, Thomas M Spackman.   

Abstract

The purpose of the study was to compare hemodynamics and postanesthetic tolerability of sevoflurane versus thiopental in electroconvulsive therapy (ECT). The design was a randomized double-blind trial in the ECT suite of a tertiary referral medical center. Thirty-one patients were randomized to either sevoflurane or thiopental induction of anesthesia for up to 6 of each subject's ECT treatments. Measurements included hemodynamics (heart rate and blood pressure), arrhythmias, posttreatment orientation, time to first breath, and posttreatment side effects. Sevoflurane compared favorably with thiopental in terms of hemodynamics and time to first breath, although there was a slightly nonsignificant trend toward faster recovery with sevoflurane. Sevoflurane was associated with significantly better postictal orientation 20 minutes after the treatment. We conclude that inhalational anesthesia with sevoflurane presents a well-tolerated alternative for ECT anesthesia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18090695     DOI: 10.1097/yct.0b013e318136e1b4

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  2 in total

Review 1.  [Anesthesia for electroconvulsive therapy].

Authors:  U Grundmann; S O Schneider
Journal:  Anaesthesist       Date:  2013-04       Impact factor: 1.041

2.  Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis.

Authors:  Taisuke Yatomi; Takahito Uchida; Akihiro Takamiya; Masataka Wada; Shun Kudo; Kazuki Nakajima; Hana Nishida; Bun Yamagata; Masaru Mimura; Jinichi Hirano
Journal:  Front Hum Neurosci       Date:  2022-07-08       Impact factor: 3.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.